What diseases and indications is Inalisate (Iheli) mainly used to treat?

Inavolisib (trade name Itovebi) is a selective PI3Kα inhibitor mainly used to treat breast cancer patients. The drug interferes with tumor cell proliferation and survival by inhibiting the PI3K α signaling pathway, thereby inhibiting tumor progression. Inalise is particularly suitable for patients with hormone receptor-positive, HER2-negative breast cancer who often experience disease recurrence or progression during or after endocrine therapy.

Inalise has shown significant efficacy in breast cancer patients carrying PIK3CA gene mutations. PIK3CA gene mutations are relatively common in breast cancer patients, accounting for about 40% of them. By targeting this gene mutation, inaliside can more accurately inhibit tumor growth, delay disease progression, and improve patient treatment effects. Genetic testing is an important step before using inalise to confirm whether the patient is eligible.

Inaliside is mainly used in patients with locally advanced or metastatic breast cancer, especially those who have relapsed after completing adjuvant endocrine therapy. In clinical applications, inaliset is usually used in combination with palbociclib and fulvestrant. This combination has shown the effect of prolonging progression-free survival and improving disease control rate in clinical trials. Combination treatment strategies can maximize drug efficacy while reducing the risk of resistance to monotherapy.

Pay attention to safety and medication management when using inaliset. Patients should regularly monitor blood sugar, liver function, blood routine and other indicators during treatment to prevent drug-related adverse reactions. In addition, patients should use it under the guidance of a professional doctor and adjust the dosage according to individual conditions. Overall, inaliset provides a precise and efficient targeted treatment option for breast cancer patients with PIK3CA gene mutations, significantly improving the prognosis of some patients.

Reference link:https://www.drugs.com